Drugs / Euvichol-Plus
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT05771779 | Oct 2023 → May 2025 | cholera, measles, rubella, typhoid fever | International Centre for Diarrhoeal Disease Research, Bangladesh | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05453253 | Jul 2022 → Feb 2024 | cholera | Epicentre | Unknown | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT07509047 Comparator | Jan 2026 → Mar 2027 expected | — | International Vaccine Institute | Recruiting | No outcome recorded |
| Phase 3 | NCT07304284 Comparator | Oct 2025 → Dec 2026 expected | — | International Vaccine Institute | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Euvichol-Plus | “oral cholera vaccine (OCV), Euvichol-Plus against V. cholerae” NCT05771779 ↗ |
| Modality | Vaccine | “Euvichol-Plus, a WHO prequalified oral cholera vaccine, contains modified killed whole cell vaccine of formalin killed Vibrio cholerae strains of O1 Inaba, O1 Ogawa and O139.” NCT05453253 ↗ |
| Route | Oral | “two doses administered orally 14 days apart for individuals aged ≥1 year.” NCT05453253 ↗ |